Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC

NCT05498896 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

146

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Atezolizumab
DRUG: Ipatasertib
DRUG: Paclitaxel
DRUG: Doxorubicin
DRUG: Cyclophosphamide

Sponsor

Queen Mary University of London

Collaborators

[object Object]
[object Object]
[object Object]